>Rabbit PAb Antibody
>Insulin Receptor / CD220 / INSR Antibody (Antigen Affinity Purified)
|Catalog||Size (Price)||Quantity||In Stock||Operation||Other Information|
Insulin Receptor / CD220 / INSR Antibody ( Antigen Affinity Purified ) Datasheet
|Order or Inquire for Insulin Receptor / CD220 / INSR Antibody product||Quality antibodies||Antibody production services|
|Detection limit is 0.5 ng/lane in WB|
|Detection limit is 0.00245 ng/well in ELISA|
Insulin Receptor / CD220 / INSR Antibody Product Information
Recombinant Human Insulin Receptor / CD220 / INSR protein (Catalog#11081-H08H)
|Antibody Type :||Rabbit Polyclonal Antibody ( Antibody Purification Platform )|
|Ig Type :||
|Formulation :||0.2 μm filtered solution in PBS with 5% trehalose|
Produced in rabbits immunized with purified, recombinant Human Insulin Receptor / CD220 / INSR (rh Insulin Receptor / CD220 / INSR; Catalog#11081-H08H; NP_000199.2; Met 1-Lys 956). Insulin Receptor / CD220 / INSR specific IgG was purified by Human Insulin Receptor / CD220 / INSR affinity chromatography.
Insulin Receptor / CD220 / INSR Antibody Usage Guide
Human Insulin Receptor / CD220 / INSR
IHC-P: 1-3 μg/mL
|Direct ELISA :||This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human INSR. The detection limit for Human INSR is approximately 0.00245 ng/well.|
|Storage :||This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Insulin Receptor / CD220 / INSR Antibody Related Products & Topics
|Molecule||Species||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Insulin Receptor/CD220||Human||Insulin Receptor/CD220 Protein, Recombinant||11081-H08H|
|Insulin Receptor/CD220||Human||Insulin Receptor/CD220 Protein, Recombinant||11086-H08H|
|Insulin Receptor/CD220||Human||INSR / CD220 Protein, Recombinant, with GST Tag||11086-H20B1|
|Molecule||Application||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|ELISA||Insulin Receptor/CD220 Antibody, Mouse MAb||11081-MM01|
|WB||Insulin Receptor/CD220 Antibody, Mouse MAb||11081-MM03|
|WB, ELISA||Rabbit Polyclonal Antibody||11081-RP01|
|WB, ELISA||Insulin Receptor / CD220 / INSR Antibody (Antigen Affinity Purified)||11081-RP02|
Insulin Receptor / CD220 / INSR Antibody Background
INSR (Insulin receptor), also known as CD220, is a transmembrane receptor that is activated by insulin. INSR belongs to theprotein kinase superfamily, and exists as a tetramer consisting of two alpha subunits and two beta subunits linked by disulfide bonds. The alpha and beta subunits are encoded by a single INSR gene, and the beta subunits pass through the cellular membrane. As the receptor for insulin with tyrosine-protein kinase activity, INSR associates with downstream mediators upon binding to insulin, including IRS1 (insulin receptor substrate 1) and phosphatidylinositol 3'-kinase (PI3K). IRS-1 binding and phosphorylation eventually leads to an increase in the high affinity glucose transporter (Glut4) molecules on the outer membrane of insulin-responsive tissues. INSR isoform long and isoform short are expressed in the peripheral nerve, kidney, liver, striated muscle, fibroblasts and skin, and is found as a hybrid receptor with IGF1R which also binds IGF1 in muscle, heart, kidney, adipose tissue, skeletal muscle, hepatoma, fibrobasts, spleen and placenta. Defects in Insulin Receptor/INSR are the cause of Rabson-Mendenhall syndrome (Mendenhall syndrome), insulin resistance (Ins resistance), leprechaunism (Donohue syndrome), and familial hyperinsulinemic hypoglycemia 5 (HHF5). It may also be associated with noninsulin-dependent diabetes mellitus (NIDDM).
- Kadowaki, T. et al., 1990, J. Biol. Chem. 265:19143-19150.
- Kan, M. et al., 1995, Diabetes. 44: 1081-1086.
- Duckworth, WC. et al., 1998,Endocr. Rev.19 (5): 608-624.
- Maddux, B A. et al., 2000, Diabetes. 49 (1): 13-9.
- Longo, N. et al., 2002, Hum. Mol. Genet.11 (12): 1465-1475.
- Ward, CW. et al., 2009, Bioessays. 31 (4): 422-434.